Alan Belicha | Chief Executive Officer
MitoPath

Alan Belicha, Chief Executive Officer, MitoPath

Alan Belicha is the CEO of MitoPath, a company focused on the development of a gene therapy company for the ultra-orphan disease Mitochondrial NeuroGastroIntestinal Encephalomyopathy or MNGIE.
 
Beyond his role at MitoPath, Alan is the Director, Business Development and Industry Engagement at Business & Entrepreneur Partnerships, at the University at Buffalo, the #1 public university in New York State. Prior to this, Alan worked in Business Development at Mount Sinai Innovation Partners (MSIP), the technology commercialization arm of the Mount Sinai Health System in New York City.  At MSIP he was responsible for evaluating early stage life science technologies, developing a commercial strategy and ultimately partnering those assets with biotech and pharma companies. During his time at Mount Sinai Innovation Partners he contributed to the licensing of ~$850M of preclinical stage assets.
 
Prior to his transition into business development, Alan obtained a Ph.D. in molecular tumor immunology at Roswell Park Comprehensive Cancer Center and completed a postdoctoral fellowship at the Icahn School of Medicine at Mount Sinai in New York City, where he also worked as a consultant in an early-stage venture fund for several years. 

Appearances:



World Orphan Drug Congress USA 2019 - Day 2 @ 12:25

Pitch 21: AAV2/8-based gene therapy for Mitochondrial NeuroGastroIntestinal Encephalomyopathy (MNGIE)

last published: 20/Mar/19 21:45 GMT

back to speakers